Background and purpose: Small vessel disease (SVD) and Alzheimer's disease (AD) are two common causes of cognitive impairment and dementia, traditionally considered as distinct processes. The relationship between radiological features suggestive of AD and SVD was explored, and the association of each of these features with cognitive status at 1 year was investigated in patients with stroke or transient ischaemic attack. Methods: Anonymized data were accessed from the Virtual International Stroke Trials Archive (VISTA). Medial temporal lobe atrophy (MTA; a marker of AD) and markers of SVD were rated using validated ordinal visual scales. Cognitive status was evaluated with the Mini Mental State Examination (MMSE) 1 year after the index stroke. Logistic regression models were used to investigate independent associations between (i) baseline SVD features and MTA and (ii) all baseline neuroimaging features and cognitive status 1 year post-stroke. Results: In all, 234 patients were included, mean (AESD) age 65.7 AE 13.1 years, 145 (62%) male. Moderate to severe MTA was present in 104 (44%) patients. SVD features were independently associated with MTA (P < 0.001). After adjusting for age, sex, disability after stroke, hypertension and diabetes mellitus, MTA was the only radiological feature independently associated with cognitive impairment, defined using thresholds of MMSE ≤ 26 (odds ratio 1.94; 95% confidence interval 1.28-2.94) and MMSE ≤ 23 (odds ratio 2.31; 95% confidence interval 1.48-3.62). Conclusion: In patients with ischaemic cerebrovascular disease, SVD features are associated with MTA, which is a common finding in stroke survivors. SVD and AD type neurodegeneration coexist, but the AD marker MTA, rather than SVD markers, is associated with post-stroke cognitive impairment.
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Introduction
Dementia is a major public health issue, affecting approximately 47 million people worldwide; by 2030 this figure will increase to approximately 75 million [1] . After Alzheimer's disease (AD), vascular dementia (VaD) is the second most common type of dementia. The pathological processes that contribute to AD and VaD differ, with primary neuronal degeneration considered to be the pathological process that contributes to AD and cerebral small vessel disease (SVD) a major contributor to VaD. Medial temporal lobe atrophy (MTA) is a major neurodegenerative dementia marker that is traditionally associated with the clinical diagnosis of AD [2] . In contrast, the radiological features of SVD encompass a wide range of imaging phenotypes, ranging from white matter changes to lacunar infarcts and enlarged perivascular spaces (EPVS) [3] .
Alzheimer's disease and SVD are usually considered distinct entities with differing neuroradiological appearances. The concept of exclusive categorizations of AD and VaD has been challenged. A recent scientific statement underscored the importance of the vascular contribution to all-cause cognitive impairment and dementia [4] , whilst observational data suggest that vascular risk factors such as hypertension and diabetes may play an important role in pathogenesis and progression of AD [5] [6] [7] .
Following stroke, a third of patients develop dementia, and up to two-thirds have some degree of persisting cognitive impairment [8] . Establishing the pathogenesis of post-stroke cognitive impairment may allow for the development of targeted therapy. The impaired cognition that follows stroke is traditionally considered to be of vascular origin; however, it seems plausible that a substantial proportion with poststroke cognitive impairment may have coexisting AD type pathology. In this regard, the evidence about vascular and neurodegenerative contributions to cognitive impairment after stroke is not definitive, and the overlap between such contributions remains overlooked [9] . Therefore, our aim was to evaluate the relationship between neuroimaging markers of AD, SVD and cognition in a cohort of patients with ischaemic stroke, extending the existing evidence.
Our specific objectives were (i) to describe the association between SVD and an exemplar AD neuroimaging marker (MTA) and (ii) to describe the association between these neuroimaging features and cognitive status 1 year after the index stroke.
Methods

Participants
Individual patient level data analyses were conducted using the Virtual International Stroke Trial Archive (VISTA). VISTA is an academic collaboration that provides access to existing anonymized trial data to perform exploratory analyses, to allow hypothesis testing and to inform the design of future clinical trials [10] .
From the VISTA resource, those patients with diagnosis of ischaemic stroke and transient ischaemic attack where magnetic resonance (MR) imaging of brain and evaluation of cognitive status (e.g. cognitive scales, clinical evaluation) were available were included. All included trials required valid consent. Clinical variables of interest were age, sex, clinical history of hypertension, diabetes mellitus, atrial fibrillation, hypercholesterolaemia, peripheral artery disease, ischaemic heart disease, cigarette smoke exposure and depression (all defined as per parent trials). Included participants had vascular, laboratory and cardiac investigation data available; characterization of stroke aetiology was assessed according to the method described in the Trial of Org 10172 (TOAST) [11] . Function was assessed at baseline (i.e. after the index stroke) and quantified using the Oxford Handicap Scale (OHS) [12] and used as a proxy for stroke severity. The OHS is a derivative of the modified Rankin Scale, which is the most common outcome measure in stroke trials.
Imaging analysis
A stroke neurologist trained in MR assessment and blinded to clinical data (FA) rated all the available scans [T1, T2, fluid-attenuated inversion recovery (FLAIR) sequences]. SVD features were rated according to STRIVE (Standards for Reporting Vascular Changes on Neuroimaging) recommendations [13] . Where the index infarct was too large to allow the rating of the SVD features, SVD ratings were performed only in the non-affected hemisphere. Lacunes were defined as round shaped cerebrospinal fluid isointense lesions measuring ≤20 mm in diameter on axial sections in the white matter, basal ganglia or brainstem as seen on T1, T2 or FLAIR sequences. White matter hyperintensities were graded according to the Van Swieten scale [14] as 0-4, combining the ratings in the anterior and posterior periventricular white matter. Brain atrophy was defined as central and cortical, and rated as none, moderate and severe against a reference MR brain template [15] . EPVS were defined as ≤2 mm round or linear cerebrospinal fluid isointense lesions (T2 hyperintense and T1/FLAIR hypointense). EPVS in basal ganglia and centrum semiovale were separately rated using a five-point ordinal scale [16] as follows: 0, no EPVS; 1, 1-10 EPVS; 2, 11-20 EPVS; 3, 21-40 EPVS; and 4, >40 EPVS. As a marker of neurodegeneration classically seen in AD, MTA was rated with coronal T1 weighted sequences as 0-4 with a validated visual scale [2] and against a reference template.
Cognitive status
Studies with cognitive assessment after 1 year of the index stroke were included. Cognitive impairment was assessed using the Mini Mental State Examination (MMSE) [17] . Cognitive impairment was defined as MMSE ≤ 26 [18] . An alternative threshold said to be more specific to dementia, MMSE ≤ 23, was also used. Patients with a baseline diagnosis of dementia were excluded from our analysis (n = 6).
Statistical analysis
After taking into account the distribution of data, Spearman's rank correlation coefficient was used to evaluate the relationship between each of the SVD MR features and MTA. MMSE scores stratified by MTA grading were described and between-group differences were analysed with the KruskalÀWallis test. To assess multivariate associations with MTA, logistic regression was used. MTA was dichotomized into groups of 0-1 (none to mild MTA) versus 2-4 (moderate to severe). Univariate associations were described between SVD features and dichotomized MTA. For our multivariate models, statistically significant (P < 0.1) variables were retained from the univariate analysis. Variables with face validity or where previous work has suggested an association with cognition, such as age, sex, history of hypertension and history of diabetes, were also included.
Univariate associations between all neuroimaging features (both SVD and MTA, considered as ordinal scales) and cognitive status were described. A multivariate model comprising significant and known associated variables as described previously was similarly created. For multivariate models adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were described; statistical significance was defined as P < 0.05.
Results
A total of 234 patients had full clinical, radiological and cognitive data. Mean (AESD) age was 65.7 (AE13.1); 145 patients (62%) were male. One hundred and ninety-five patients had ischaemic stroke as the index event (83%), of whom 94 (40%) had lacunar stroke subtype (Table 1) .
One hundred and four (44%) patients were assessed to have moderate to severe MTA (a score of 2-4). Compared to patients with no to mild MTA, those with moderate to severe MTA were older (60.2 vs. 70.5 years, P < 0.001), more frequently had a history of hypertension (73% vs. 87%, P < 0.012), had a higher grade of disability at baseline (median OHS 1 vs. 2, P < 0.001) and more frequently had evidence of SVD neuroimaging features (all P < 0.001) ( Table 1) .
Medial temporal lobe atrophy had positive correlations with all SVD features. MTA was most closely related to central brain atrophy (q = 0.64, P < 0.001) and white matter changes (q = 0.60, P < 0.001); the weakest correlations were with number of lacunes (q = 0.32, P < 0.001) and centrum semiovale EPVS (q = 0.35, P < 0.001) ( Table 2 ).
In logistic regression models, after adjusting for age, sex, hypertension and diabetes mellitus, several radiological features of SVD remained independently associated with MTA (Table 3) . Only the association between centrum semiovale EPVS and MTA failed to reach statistical significance in our sample (OR 1.47; 95% CI 0.99-2.18, P = 0.057), even though the magnitude of effect was similar to the unadjusted analysis.
One year after the index stroke, 101 (43%) patients had cognitive impairment as defined by MMSE ≤ 26, whereas 67 (29%) had MMSE ≤ 23, suggestive of dementia. The distribution of MMSE scores amongst MTA grades showed a decline in cognitive performance with increasing severity of MTA (P < 0.001, Fig. 1 ). In the univariate logistic regression models, all the radiological variables were associated with the development of cognitive impairment at 1 year, and only lacunes were not significantly associated with dementia. However, after adjustment for age, sex, disability status, hypertension and diabetes mellitus, only MTA remained independently associated with MMSE ≤ 26 (OR 1.94 per point increase in MTA score; 95% CI 1.28-2.94) and with MMSE ≤ 23 (OR 2.31; 95% CI 1.48-3.62) ( Table 4) .
Discussion
It was found that MTA is a common finding in clinical stroke trial populations and has important implications for cognition status at 1 year post-stroke. MTA and SVD may coexist, but MTA seems to have a stronger association with cognitive status than SVD markers.
To date, few studies have specifically addressed the potential overlap between radiological markers of SVD and neurodegeneration markers in a population of patients with ischaemic stroke. In our clinical trial based population, MTA was present in 40% of patients, a proportion comparable with previous studies [19] [20] [21] . It was found that MTA strongly correlated with brain features that may be seen in any dementia process, e.g. atrophy. However, correlation of MTA with neuroimaging features usually described as exclusively relating to small vessel cerebrovascular disease, e.g. lacunes and basal ganglia EPVS, was also demonstrated. The independent association between SVD radiological markers and MTA alludes to a potential overlap between neurodegenerative and neurovascular pathology. Other groups have also reported this shared pathology, with white matter changes described in patients with AD [22] and MTA present in more than half of elderly stroke survivors [20, 21] and in patients with diagnosis of vascular dementia [23] . Indeed, many groups would say that most post-stroke cognitive impairment can be predominantly classified as vascular dementia. In our study, MTA severity was independently associated with cognitive impairment and dementia. It is perhaps unsurprising that small vessel cerebrovascular features have limited association with cognition after correction for vascular risk factors, as SVD is so closely related to hypertension and diabetes mellitus. Our results support that SVD and AD frequently coexist but are not synonymous, as MTA still demonstrated cognitive association even after correction for vascular risk factors. Our results are in line with a previous study that showed MTA rather than white matter changes as the strongest marker of long term memory function after stroke [24] .
However, pre-stroke assessment of cognitive status was not available. It is possible that some participants had unrecognized cognitive issues, given the high prevalence of MTA. However, it seems unlikely that many of the participants will have had frank dementia at study recruitment. Furthermore, there is no validated assessment of pre-stroke cognition [25] . Prestroke dementia may not be diagnosed until after presenting to stroke services and it could be argued that patients with MTA had AD prior to their index stroke event. This argument is not supported by our data; despite almost half of our included population exhibiting moderate to severe MTA, only six patients had a clinical diagnosis of dementia at baseline assessment. At 1 year, around a third of the study patients had MMSE ≤ 23, suggestive of dementia. This finding suggests that pre-existing MTA may act as a marker of 'brain frailty' pre-disposing a person to development of long term cognitive deficits. In this cognitively vulnerable state, incident stroke may be a sufficient cognitive 'stressor' to lead to clinical cognitive impairment. MTA may therefore represent a useful in vivo biomarker to stratify stroke patients in clinical trials investigating cognitive outcomes. Such trials should include also MTA assessment as a baseline radiological marker.
The strengths of our study are the standardized assessment of radiological variables with extensively validated radiological scales and the reproducibility of our methodology in clinical practice. The validated visual ratings used are widely adopted, and cognitive function was screened using the MMSE, which is widely used by many stroke physicians. Although it is recognized that MMSE is not a substitute of a comprehensive cognitive evaluation, in the context of clinical practice it is a useful and practical tool to detect those patients that require further cognitive assessment. Furthermore, it has been shown by a recent meta-analysis that MMSE is a reasonable tool to detect cognitive impairment amongst cognitive scales for evaluation of stroke patients [18] .
The main limitation of the study was the relatively small sample size. Our study may not have the statistical power to detect weaker but clinically meaningful associations with cognitive outcomes (e.g. SVD markers and cognition). However, the latest systematic review and meta-analysis of factors associated with post-stroke dementia examined about 600 patients with MTA assessment and found that MTA was associated with an increased risk of both pre-and poststroke dementia [26] . Although comparable to previous similar studies [20, 21, 24] , it is acknowledged that the sample size of the present study was small. Nonetheless, our result considerably expands the dataset of the aforementioned meta-analysis, adding more than 200 stroke patients with standardized MTA and SVD ratings. Moreover, the qualitative evaluation of MTA and SVD is easily transferable to clinical practice.
It is acknowledged that important factors associated with post-stroke cognitive impairment, such as education level and stroke severity, were not included in the analysis. As a retrospective study of existing datasets, only variables evaluated in the original trials were available, and education level was not routinely assessed in the parent trials. Regarding stroke severity, function level after stroke (i.e. disability) was inserted in the analysis as a proxy of stroke severity. The use of a study population from clinical trials probably gave us a selected stroke population; however, the advantage of using a trials dataset is in the quality of the collected data, which is often more complete than clinical registries. Finally, it is underscored that with cognitive data at a single time point it is only possible to describe associations between factors of interest. A prospective cohort study could give more information on prognosis and possible directions of causation.
In conclusion, it has been demonstrated that MTA, a radiological marker of AD, is frequent amongst stroke survivors and is associated with radiological features of SVD, supporting a substantial overlap between vascular and degenerative pathology. Increasing severity of MTA is associated with short to medium term post-stroke cognitive impairment and seems to have more weight than SVD features. Careful evaluation of radiological features pertaining to both AD and SVD in patients with stroke may help risk stratification for clinical practice and studies.
